The Latest Breaking News on Pharma

Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble.

The pharma industry has experienced tremendous growth in recent years and should continue to grow amid the integration of advanced technologies. Hence, pharma stocks Eli Lilly (LLY), Takeda Pharmaceutical (TAK), Catalyst Pharmaceuticals (CPRX), Poseida Therapeutics (PSTX), and Voyager Therapeutics (VYGR) might be worth buying right now. Read on.

A pharmaceutical company selling the only drug approved to prevent preterm birth said Tuesday that it would withdraw the medicine from the market.

George Freeman claimed the BGI Group was a “danger point” in science and technology

The maker of an unproven drug intended to prevent premature births says it will voluntarily remove the product from the United States

Sanofi stock could shine in 2023 as the French pharma tees up a rival to Pfizer's experimental RSV vaccine for newborn babies.

For years, the FDA has defended its efforts to intercept prescription drugs coming from abroad by mail as necessary to keep out dangerous opioids, including fentanyl.

EMA says relocation of sex workers to area near its HQ could bring problems associated with red light district

Strong fundamentals and bright prospects of AstraZeneca (AZN), trading below $100 a share, could help investors secure decent risk-adjusted returns on their investments in a choppy market environment. Read on….

Two of Merck's new drugs could generate north of $10 billion in peak sales, an analyst said Tuesday.

The healthcare industry is expanding, fueled by the increasing demand and advancements such as personalized medicines and telehealth. Hence, fundamentally strong healthcare stocks Abbott Laboratories (ABT), Centene (CNC), and McKesson (MCK) might be worth buying in 2023. Read more.